Time to workforce exit after a Parkinson's disease diagnosis
(2023) In npj Parkinson's Disease 9. p.1-8- Abstract
The impact of Parkinson's disease (PD) on workforce participation has received little attention even though demographic, lifestyle, and political changes together will result in an increased burden of PD on the working-age population. In this study, we investigate workforce survival after a PD diagnosis, as well as what demographic factors that are associated with workforce survival. As an exploratory outcome, we investigate workforce survival in persons with and without device-aided treatment (DAT). This is a nested case-cohort study based on Swedish national data from 2001-2016. Controls were matched on year of birth, sex, and municipality of residence. The used registers contain data on demographics, social insurance, in- and... (More)
The impact of Parkinson's disease (PD) on workforce participation has received little attention even though demographic, lifestyle, and political changes together will result in an increased burden of PD on the working-age population. In this study, we investigate workforce survival after a PD diagnosis, as well as what demographic factors that are associated with workforce survival. As an exploratory outcome, we investigate workforce survival in persons with and without device-aided treatment (DAT). This is a nested case-cohort study based on Swedish national data from 2001-2016. Controls were matched on year of birth, sex, and municipality of residence. The used registers contain data on demographics, social insurance, in- and outpatient visits, filled drug prescriptions, and cause of death on the person-level. A total of 4781 persons with PD and 23,905 controls were included. The median survival until all-cause workforce exit was 43 months among persons that were workforce-active at the time of PD diagnosis, compared to 66 months in non-PD controls. Being female, ≥50 years old at diagnosis, or having a lower education were contributing factors to health-related workforce exit. Persons receiving DAT during follow-up exhibited shorter workforce survival than controls. However, this needs further investigation, particularly as patients have generally already left the workforce at the time for start of DAT. It is evident that PD has grave negative effects on workforce participation. Thus, supportive measures need to start at an early stage after diagnosis, and the development of new interventions is urgently needed.
(Less)
- author
- Timpka, Jonathan LU ; Dahlström, Örjan ; Nilsson, Maria H LU ; Iwarsson, Susanne LU and Odin, Per LU
- organization
-
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- Restorative Parkinson Unit (research group)
- Active and Healthy Ageing Research Group (research group)
- Clinical Memory Research (research group)
- EpiHealth: Epidemiology for Health
- National Graduate School on Ageing and Health (research group)
- publishing date
- 2023-05-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- npj Parkinson's Disease
- volume
- 9
- article number
- 72
- pages
- 1 - 8
- publisher
- Springer Nature
- external identifiers
-
- scopus:85158163642
- pmid:37156779
- ISSN
- 2373-8057
- DOI
- 10.1038/s41531-023-00513-0
- language
- English
- LU publication?
- yes
- additional info
- © 2023. The Author(s).
- id
- 6747887b-4d14-41d2-90d8-d3e9eb82b1a4
- date added to LUP
- 2023-05-10 18:20:35
- date last changed
- 2024-09-07 10:53:53
@article{6747887b-4d14-41d2-90d8-d3e9eb82b1a4, abstract = {{<p>The impact of Parkinson's disease (PD) on workforce participation has received little attention even though demographic, lifestyle, and political changes together will result in an increased burden of PD on the working-age population. In this study, we investigate workforce survival after a PD diagnosis, as well as what demographic factors that are associated with workforce survival. As an exploratory outcome, we investigate workforce survival in persons with and without device-aided treatment (DAT). This is a nested case-cohort study based on Swedish national data from 2001-2016. Controls were matched on year of birth, sex, and municipality of residence. The used registers contain data on demographics, social insurance, in- and outpatient visits, filled drug prescriptions, and cause of death on the person-level. A total of 4781 persons with PD and 23,905 controls were included. The median survival until all-cause workforce exit was 43 months among persons that were workforce-active at the time of PD diagnosis, compared to 66 months in non-PD controls. Being female, ≥50 years old at diagnosis, or having a lower education were contributing factors to health-related workforce exit. Persons receiving DAT during follow-up exhibited shorter workforce survival than controls. However, this needs further investigation, particularly as patients have generally already left the workforce at the time for start of DAT. It is evident that PD has grave negative effects on workforce participation. Thus, supportive measures need to start at an early stage after diagnosis, and the development of new interventions is urgently needed.</p>}}, author = {{Timpka, Jonathan and Dahlström, Örjan and Nilsson, Maria H and Iwarsson, Susanne and Odin, Per}}, issn = {{2373-8057}}, language = {{eng}}, month = {{05}}, pages = {{1--8}}, publisher = {{Springer Nature}}, series = {{npj Parkinson's Disease}}, title = {{Time to workforce exit after a Parkinson's disease diagnosis}}, url = {{http://dx.doi.org/10.1038/s41531-023-00513-0}}, doi = {{10.1038/s41531-023-00513-0}}, volume = {{9}}, year = {{2023}}, }